NATCO Pharma Navigates Growth with Strategic Acquisitions and Innovative Pipeline in Q3 FY26

NATCO Pharma Limited has demonstrated a robust performance in the third quarter of fiscal year 2026, showcasing strategic agility and a clear vision for diversified growth. The company reported a consolidated total revenue of INR 705.4 crores for the quarter ended December 31, 2025, a notable increase from INR 651.1 crores in the corresponding period of the previous year. This growth was accompanied by a healthy EBITDA of INR 216.8 crores, achieving a margin of 30.7%, and a net profit of INR 151.3 crores. These figures underscore NATCO's resilience and strategic pivot in a dynamic pharmaceutical landscape, particularly as it navigates the evolving market post-Revlimid.

The quarter's performance was significantly bolstered by strong contributions from its core segments. Pharma Export Formulations emerged as the largest revenue driver, contributing INR 421.4 crores, representing 59.7% of the total revenue. Domestic Pharma Formulations also showed solid growth, reaching INR 119.8 crores, or 17.0% of the total. API Revenue stood at INR 64.3 crores (9.1%), while Crop Health Sciences contributed INR 28.5 crores (4.0%). Other operating and non-operating income added INR 71.3 crores (10.1%), further diversifying the revenue streams. This balanced performance reflects NATCO's efforts to build a more stable and diversified earnings base.

Strategic Expansion and Product Innovation

NATCO Pharma's strategic initiatives during Q3 FY26 highlight its commitment to both geographical expansion and product innovation. A significant move was the culmination of a strategic acquisition of a 35.75% stake in Adcock Ingram Holdings Limited, South Africa. This acquisition is a cornerstone of NATCO's strategy to expand its geographical footprint and diversify its profit base. Adcock's revenue for the first half of its financial year, ending December 31, 2025, was INR 2,464 crores, with a profit after tax of INR 198 crores. NATCO accounted for INR 29.65 crores as its share of profit for the short holding period, which adjusted to INR 10.90 crores after a one-time amortization of INR 18.75 crores. Management anticipates this acquisition will contribute INR 35-40 crores PAT per quarter to NATCO's balance sheet going forward, signaling a steady and strong base business.

In the domestic market, NATCO launched Risdiplam, a critical treatment for Spinal Muscular Atrophy. The company is also poised for significant growth with its generic GLP-1 products, Ozempic (for diabetes) and Wegovy (for weight loss). The generic Ozempic has received SEZ committee clearance, with DCGI approval expected shortly, paving the way for its market launch. Clinical trials for Wegovy are nearing completion, with approval filing expected soon. These launches are projected to be major growth drivers, with an internal target for the domestic business to grow more than 20% this year, primarily fueled by semaglutide. The company is outsourcing the fill and finish capacity for these products in India and is also exploring out-licensing opportunities.

Pioneering Investments in Cell & Gene Therapy

Beyond traditional pharmaceuticals, NATCO is making bold strides into the future of medicine through strategic investments in Cell & Gene Therapy. The company has invested US$ 8 million in eGenesis, a biotechnology firm focused on xenotransplantation, developing human-compatible organs for transplant. Early trial results for eGenesis are promising, with one patient showing good progress for six months. Management views this as a high-risk, high-reward 'multi-bagger' opportunity, with potential significant developments within the next 2-3 years.

Further investments include US$2 million in Cellogen Therapeutics for advanced CAR-T cell therapies, US$ 1 million in Eyestem for experimental treatments for dry Age-Related Macular Degeneration, and US$ 1 million in Stero Therapeutics for novel therapies for metabolic diseases. These investments underscore NATCO's commitment to anticipating sector trends and positioning itself at the forefront of medical innovation.

Operational Efficiency and Future Outlook

NATCO has also focused on operational efficiency and regulatory compliance. The company successfully resolved the FDA warning letter for its Kothur facility and received clearance for the Mekaguda inspection in 2025. While the Chennai facility awaits classification, management believes the observations were procedural. The Vizag formulation facility is also due for an inspection this year. These efforts ensure robust manufacturing capabilities to support future growth.

Looking ahead, NATCO Pharma has provided clear guidance for FY26, expecting total revenue to be between INR 4,200-4,300 crores and PAT to be in the range of INR 1,280-1,300 crores. The de-merger of the Crop Health Sciences division is targeted for completion in the next 8-9 months, aiming to unlock further value. With a strong cash position of INR 2,500 crores, management is keen on preserving capital for further large acquisitions, indicating a disciplined approach to capital allocation focused on strategic growth rather than short-term buybacks. The company's R&D spend typically hovers around 8% of sales, reflecting its continuous investment in a complex generic pipeline.

NATCO Pharma's Q3 FY26 performance and strategic roadmap demonstrate a company actively transforming its business model. By diversifying its revenue streams, expanding geographically, and investing in cutting-edge therapies, NATCO is building a resilient and future-ready enterprise. The focus on both immediate market opportunities and long-term disruptive innovation positions NATCO for sustained growth and value creation for its shareholders.